2025-05957NoticeWallet

Big Pharma import smackdown: Bans loom for rival wonder drugs?

Published Date: 4/8/2025

Notice

Summary

The U.S. International Trade Commission got a complaint from BioMarin Pharmaceutical about some imported drug products that might be breaking the rules. This affects companies like Ascendis Pharma and Wacker Biotech, and the Commission is asking the public to share their thoughts on the issue soon. If the complaint moves forward, it could lead to import bans and legal orders within the next 60 days, possibly impacting drug sales and market competition.

Analyzed Economic Effects

2 provisions identified: 0 benefits, 2 costs, 0 mixed.

Possible import ban and cease orders

BioMarin filed a complaint on April 2, 2025 asking the U.S. International Trade Commission to issue a limited exclusion order and cease and desist orders for certain imported drug products. The complaint asks that these orders (and a bond) apply during the 60-day Presidential review period, which could bar importation and sale of the named products while the review is ongoing.

Requested bond on alleged infringing imports

The complainant requested that the Commission impose a bond on respondents' alleged infringing articles during the 60-day Presidential review period. If granted, respondents would need to post a financial bond covering the alleged infringing imports for the duration of that review.

Personalized for You

How does this regulation affect your finances?

Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Key Dates

Published Date
4/8/2025

Department and Agencies

Department
Independent Agency
Agency
International Trade Commission
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register